Swiss Specialty Stores Stock News

If you are wondering whether Nestlé is quietly becoming good value again, or if it is still priced for safety rather than upside, you are not alone. Plenty of long term investors are asking the same question. The stock is up 4.9% year to date and 7.3% over the last year, but those gains sit against a 21.5% slide over 3 years and a 9.5% drop over 5 years, suggesting the market is still recalibrating its expectations. Recent months have seen Nestlé in the headlines for portfolio reshaping and...

Newron Pharmaceuticals has initiated its ENIGMA-TRS 2 global Phase III trial of evenamide as an add-on therapy for treatment-resistant schizophrenia, following US FDA and IRB approvals, with the first site at UCLA’s Semel Translational Research Center for Neuropsychiatry. The study’s focus on rigorously defined treatment-resistant patients and evenamide’s targeted sodium-channel mechanism highlights its potential differentiation from existing antipsychotic options. Next, we’ll explore how...

In early December 2025, Holcim completed acquisitions of Thames Materials in West London and a majority stake in A&S Recycling in Germany, and agreed to buy a demolition materials recycler in Northwest France, adding around 1.3 million tons of annual permitted processing capacity to its European network. By integrating these recycling businesses into its ECOCycle® circular construction platform, Holcim is materially expanding access to low‑carbon, recycled construction solutions across...

EPIC Suisse (SWX:EPIC) has just wrapped up a CHF 70 million follow on equity offering at about CHF 80 a share. This deal could subtly reset how investors think about its valuation. See our latest analysis for EPIC Suisse. Despite the modest discount to the CHF 80 offer price, the current CHF 81.8 share price and flat year to date share price return sit alongside a much stronger 1 year total shareholder return of 9.7 percent and robust 3 year total shareholder return of 53.9 percent. This...

As European markets show mixed returns with the STOXX Europe 600 Index inching higher on hopes of interest rate cuts, investors are keenly observing economic indicators such as inflation and GDP revisions. In this environment, identifying undervalued stocks can be a strategic move, as these equities may offer potential for growth when market conditions stabilize.

It's not a stretch to say that Emmi AG's ( VTX:EMMN ) price-to-earnings (or "P/E") ratio of 18.1x right now seems quite...

Dottikon ES Holding (VTX:DESN) has had a great run on the share market with its stock up by a significant 18% over the...

It is hard to get excited after looking at Clariant's (VTX:CLN) recent performance, when its stock has declined 12...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Vetropack Holding AG's ( VTX:VETN ) price-to-earnings (or "P/E") ratio of 28.5x might make it look like a sell right...

Basilea Pharmaceutica's (VTX:BSLN) stock is up by a considerable 17% over the past month. Given that the market rewards...

If you want to compound wealth in the stock market, you can do so by buying an index fund. But investors can boost...

Sika (SWX:SIKA) just pulled back the curtain on its Fast Forward program, a multi year push to digitize its value chain, streamline operations, and reshape its footprint, especially in China. See our latest analysis for Sika. The Fast Forward announcement lands after a tough stretch, with the share price down sharply on a year to date basis and the one year total shareholder return also deeply negative. This suggests sentiment has cooled even as management signals a profitability reset. If...

It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...

ABB (SWX:ABBN) just bought back nearly 300,000 shares as part of its ongoing 2025 repurchase program, a steady signal that management prefers returning cash to investors instead of chasing every acquisition opportunity. See our latest analysis for ABB. That steady buying has come alongside firm price momentum, with the share price at CHF 58.68 and a robust year to date share price return of 19.37 percent. The five year total shareholder return of 191.81 percent shows that ABB’s long term...

Cosmo Pharmaceuticals has reported strong top-line Phase III results for clascoterone 5% topical solution in male androgenetic alopecia and, together with Glenmark Pharmaceuticals, secured European Commission marketing authorization for Winlevi (clascoterone 10 mg/g cream) to treat acne vulgaris in 17 countries. These developments highlight clascoterone’s potential as a versatile, first-in-class topical androgen receptor inhibitor across both hair loss and acne, expanding Cosmo’s...

Temenos (SWX:TEMN) has quietly climbed about 6% over the past week and more than 30% in the past 3 months, putting fresh attention on whether this banking software specialist’s rebound still has room to run. See our latest analysis for Temenos. That recent momentum builds on a solid recovery trend, with a strong 90 day share price return helping push year to date gains higher. A 1 year total shareholder return above 35% suggests confidence is slowly coming back after a tougher multi year...

Adecco Group (SWX:ADEN) has been drifting lower over the past month, and that quiet slide is exactly why the stock is interesting now, especially given its improving earnings backdrop and deep valuation discount. See our latest analysis for Adecco Group. At around CHF 21.96 per share, Adecco’s roughly 6 percent 3 month share price decline contrasts with stabilising year to date performance, while a 5 year total shareholder return near minus 48 percent shows how heavily sentiment has reset...

Nestlé (SWX:NESN) has been quietly grinding higher this year, and that slow, steady move is starting to catch investors attention as they reassess what they are paying for its global food empire. See our latest analysis for Nestlé. After a soft patch in prior years, Nestlé’s roughly mid single digit year to date share price return has been backed by improving sales and earnings, hinting that investors are slowly rebuilding confidence after a weaker three year total shareholder return. If...

The Cosmo Pharmaceuticals N.V. ( VTX:COPN ) share price has done very well over the last month, posting an excellent...

Roche Holding (SWX:ROG) has quietly outperformed the broader market over the past month, and that steady climb is catching investor attention as they reassess what they are paying for its earnings power. See our latest analysis for Roche Holding. That steady run has pushed Roche Holding to a share price of $310.1, with a 30 day share price return of 17.46 percent and a 1 year total shareholder return of 24.99 percent. This suggests that momentum is building as investors grow more comfortable...

When you see that almost half of the companies in the Machinery industry in Switzerland have price-to-sales ratios (or...

If you are wondering whether Alcon is quietly becoming a bargain, or if the recent noise around the stock is just that, noise, this section will walk you through what the market might be missing. After a choppy year that still leaves the share price down around 17.8% over 12 months and 16.3% year to date, the stock has shown signs of life with an 8.4% gain over the last month, despite being flat over the past week. Recent headlines have focused on Alcon expanding its portfolio of vision care...

Cosmo Pharmaceuticals (SWX:COPN) is back on investor radar after two key catalysts: strong Phase III data for its Clascoterone 5% male hair loss treatment and European approval of Winlevi for acne across 17 countries. See our latest analysis for Cosmo Pharmaceuticals. The market has taken notice, with the share price jumping to about CHF 78.3 and a strong 1 day share price return of roughly 19 percent, reinforcing an already solid one year total shareholder return near 30 percent and...